Related Experiment Video
Updated: Aug 9, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Combined aspirin and clopidogrel resistance associated with recurrent coronary stent thrombosis
Christian Templin1, Arnd Schaefer, Burkhard Stumme
1Department Cardiology and Angiology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. templin.christian@mh-hannover.de
Insights
This case study highlights a patient with combined Clopidogrel and aspirin resistance, experiencing recurrent stent thrombosis despite escalating doses. Identifying such patients is crucial for alternative treatment strategies.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute ST-elevation myocardial infarction (STEMI) management often involves dual antiplatelet therapy (DAPT) with aspirin (ASA) and Clopidogrel.
- Drug resistance can compromise treatment efficacy, leading to adverse cardiovascular events.
Observation:
- A 72-year-old woman with STEMI developed recurrent stent thrombosis despite standard and escalated DAPT regimens.
- Platelet function studies revealed resistance to both aspirin and Clopidogrel.
Findings:
- The patient exhibited dose-independent aspirin resistance and impaired platelet inhibition with Clopidogrel, suggesting combined drug resistance.
- Switching to coumadin and continued aspirin therapy resulted in clinical stability.
Implications:
- This case suggests the existence of a patient subgroup with combined Clopidogrel and aspirin resistance.
- Routine platelet function testing may be warranted in patients with recurrent thrombotic events on DAPT.
- Alternative antithrombotic strategies are essential for managing patients with dual antiplatelet resistance.
Abstract:
We report about a 72-year-old woman who was admitted to our hospital because of an acute ST-elevation myocardial infarction (STEMI). At admission, she received a loading dose of 300 mg Clopidogrel and 500 mg aspirin (ASA) prior to angioplasty with stenting of a 90% diameter stenosis of the proximal right coronary artery. After intervention, 75 mg Clopidogrel and 300 mg ASA OD were continued. Three days later, she developed a recurrent acute STEMI due to stent thrombosis and a second stent implantation was performed. The dose of Clopidogrel and ASA remained unchanged. Three days later, the patient suffered a third STEMI due to a restent thrombosis and additional stent implantation was performed. The dose of Clopidogrel and ASA was increased to 75 mg BD and 500 mg OD. Platelet function analysis and aggregation studies demonstrated dose-independent ASA resistance. ADP-induced aggregation showed a short-term platelet inhibition with subsequent rapid normalisation, thus suggesting Clopidogrel resistance. Therefore, the treatment was changed to coumadin and ASA 100 mg OD. Since then, the patient has been clinically stabile. Our case indicates for the first time the existence of a subgroup of patients with combined Clopidogrel and ASA resistance. We conclude that identification of these patients is required and alternative therapeutic options have to be considered.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Venous Thrombosis III: Interprofessional Care
